Abbott Laboratories (ABT) is facing fresh legal challenges in connection with its sales and marketing of anti-seizure drug Depakote. The Abbott Park, Ill., company last year set aside $1.5 billion to cover a potential settlement stemming from a Justice Department-led investigation of allegations that the company promoted Depakote for unauthorized uses. A final settlement is pending. Now, attorneys general in eight states have formed a committee to investigate whether Abbott’s Depakote sale and marketing violated various state consumer-protection and other laws, the company disclosed Tuesday.
